A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
about
Desensitization: Overcoming the Immunologic Barriers to TransplantationHLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating TregsUse of polyclonal/monoclonal antibody therapies in transplantation.The importance of non-HLA antibodies in transplantation.Impact of Immune-Modulatory Drugs on Regulatory T Cell.Immunosuppression and adult heart transplantation: emerging therapies and opportunities.Renal transplantation in sensitized children and young adults: a nationwide approach.Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.Tocilizumab (Anti-IL-6R) Suppressed TNFα Production by Human Monocytes in an In Vitro Model of Anti-HLA Antibody-Induced Antibody-Dependent Cellular Cytotoxicity.IL-21 Receptor Antagonist Inhibits Differentiation of B Cells toward Plasmablasts upon Alloantigen Stimulation.Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation.T Follicular Helper Cells As a New Target for Immunosuppressive Therapies.Desensitisation strategies in high-risk children before kidney transplantation.Advances in the immunology of heart transplantation.Transplantation: IdeS to desensitize organ allograft recipients.Antibody-mediated rejection: New approaches in prevention and management.Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
P2860
Q30397952-9CBE6213-027B-4A19-AF72-143774FC4423Q33786811-2F47174A-1878-44BD-906F-D9176B9B0541Q38769922-6944537F-FF68-43E4-B1AF-ECF1D7E74B45Q38877375-8B936214-8FD5-4B01-B3C4-416B3D8290A9Q38918124-B8E65701-A6C4-4EA0-B6E6-FBDF4814CFD0Q39029380-A5B8DA13-D648-4A83-AA03-F9A96FF59BC9Q39289605-C3B9FD15-1692-451F-8D6C-316900065C58Q39366396-70230CCB-5268-4A75-9918-3E89FBB28876Q40749159-70322BDF-A893-42BC-8A69-4CD9EBA32B4DQ41861341-34D12AFA-25CA-4011-8C0E-83C2EEF591D9Q42263289-1B4F242B-6263-480C-99CC-89E791E31C8AQ46409439-E73F2517-B51A-4D01-9D9B-0726D5912B9FQ47109235-D4E9B5A1-23EE-4BAD-B62F-5176C08EC47CQ47563660-5F7FB621-728D-4698-A7D4-CF8729FC4666Q49659896-F777F3FE-4AB1-4D94-B93E-81F816355197Q50173566-35B072B9-D12C-4FDF-B37F-2C1F4E50C6C4Q52401610-3BDDE25E-1962-4662-BB58-C000C900756BQ53504304-6B0AA293-20F3-45C8-99F5-B1E0F6FA9461
P2860
A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A Phase I/II Trial of the Inte ...... icult to Desensitize Patients.
@en
A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal
@nl
type
label
A Phase I/II Trial of the Inte ...... icult to Desensitize Patients.
@en
A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal
@nl
prefLabel
A Phase I/II Trial of the Inte ...... icult to Desensitize Patients.
@en
A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal
@nl
P2093
P1433
P1476
A Phase I/II Trial of the Inte ...... icult to Desensitize Patients.
@en
P2093
Alice Peng
Ashley A Vo
Dechu Puliyanda
Joseph Kahwaji
Kristen Cisneros
Mieko Toyoda
Nancy Reinsmoen
P304
P356
10.1097/TP.0000000000000741
P577
2015-05-25T00:00:00Z